

2025 BPD @ Singapore

生物药工艺发展大会

Biopharmaceutical Bioprocess Development Summit


September 24-26, 2025 @ MBS Sands Convention Center

ORGANIZER  ENMORE BIO

CO - ORGANIZER



LISURE 利穗



SPONSOR



25+

KEYNOTE SPEECH

5+

PANEL DISCUSSION

50+

SPEAKER

20+

BOOTH

About BPD

The BPD Biopharmaceutical Bioprocess Development Summit is Asia's leading event focused on end-to-end biologics process development and commercialization. Initiated by Enmore BIO and in collaboration with co-organizers WuXi Biologics, WuXi XDC, Duoning, and Lisure, BPD is held across Shanghai, Beijing, Chengdu, and Singapore, featuring both main annual conference and regional forums.

The BPD2024 main summit in Shanghai welcomed 5,000 participants from biopharma, biotech, and upstream suppliers, combining exhibition, conference, and networking to drive CMC and chain collaboration.

The 2025 BPD@Singapore will be held on September 24–26, bringing together top biopharma, pharma and suppliers from China, APAC, Europe, and North America to explore strategies for internationalizing biologics manufacturing.



2025BPD
Shanghai-Beijing-Chengdu China

2025BPD @ Singapore



About BPD

2025BPD@Singapore
生物药工艺发展大会
Biopharmaceutical Bioprocess Development Summit



Andy Tan

Principal Scientist and Group
Leader
*Bioprocessing Technology
Institute*



David K. Leahy

Vice President Drug
Substance Development
Biohaven



Morris Rosenberg

CEO
MRBC Consulting



Xiaoping Cao

CEO
*IntelliScope
PharmaSolutions*



Tu Bing

Bioproduct Inspection
Group Team Leader
*Zhejiang Provincial Drug
Inspection Center*



Jimmy Li

CEO
WuXi XDC



Yuhua Hu

Head of US EU CMC
Management
WuXi XDC



Chris Chen

CEO
WuXi Biologics



Sherry Gu

CTO
WuXi Biologics



Zhang Wei

Principal Scientist & Group
Leader Downstream
Processing
*Bioprocessing Technology
Institute (BTI)*



Yang Yuansheng

Senior Principal Scientist II
*Bioprocessing Technology
Institute (BTI)*



Sandra Poole

Chief Operating Officer
Mythic Therapeutics



Dinesh Khokal

Global GxP Surveillance &
Quality External Affairs
Global Technical Operations-
Quality Excellence
BeiGene Singapore



Guang Hu

VP of R&D
IASO



Xuezhi Bi

Associate Professor
Senior Principal Scientist I,
Group Leader
Analytical Science &
Technologies (Protein
Analytics)
*Bioprocessing Technology
Institute (BTI)*



Niki Wong

Director, Global Technical
Operations CMC, Product
Development Science &
Technology
Abbvie

BPD Website: <https://www.bpdx.cn/Singapore>

Become a speaker: BPD_BIOPROCESS@enmore.com

2025BPD@Singapore Agenda

AM September 24		PM September 24	
BioTour to WuXi XDC SG (<i>by Invitation only</i>) Organized by WuXi XDC		Closed-door Symposium & Reception (<i>by Invitation only</i>) Organized by WuXi XDC	
AM September 25		PM September 25	
BPD Opening Ceremony and Planetary Session		Session1-BPD Forum	Session2- BPD Roadshow
Innovation in Commercial Production of Biologics		XDC Innovation and Development Organized by WuXi XDC	Advanced Technologies, Products and Services for the Upstream of Biopharmaceutical Industry
09:00-09:05 Opening Remarks		13:00-13:25 Keynote Speech	13:00-14:00 Panel Discussion: Supply Chain Stability and Application of More Innovative Technologies
09:05-09:30 Keynote Speech: Biopharma Process Innovation and Global Manufacturing Speaker: Chris Chen, CEO, WuXi Biologics		13:25-13:50 Keynote Speech	Panelist: Chris Lee, Site Head, WuXi Biologics
09:30-09:55 Keynote Speech: Biological Market Access and CMC Regulations in Singapore		13:50-14:15 Keynote Speech	Niki Wong, Director, Global Technical Operations CMC, Product Development Science & Technology, Abbvie
09:55-10:40 Panel Discussion: How to Consider for Biologics Multi-Site Production: Addressing Future Global Commercialization Challenges Panelist: Chris Chen, CEO, WuXi Biologics Jimmy Li, CEO, WuXi XDC		14:15-14:40 Keynote Speech	14:00-14:15 Roadshow
10:40-11:00 Networking		14:40-15:20 Networking	14:15-14:30 Roadshow
New Technologies for the Development of Next-generation Biologics		15:20-15:45 Keynote Speech	14:30-15:20 Networking
11:00-11:30 Keynote Speech: From Craft to Engine: The Evolving Role of ADC Manufacturing in Biotech Innovation and Access Speaker: Sandra Poole, Chief Operating Officer, Mythic Therapeutics		15:45-16:10 Keynote Speech	15:20-15:35 Roadshow
11:30-12:00 Keynote Speech: ADCs in the mid-21st Century: Hitting the Tipping Point Speaker: Dr. Morris Rosenberg, CEO, MRBC Consulting		16:10-17:00 Panel Discussion Panel Discussion Moderator: Sherry Gu, CTO, WuXi Biologics	15:35-15:50 Roadshow
		Speakers: David K. Leahy, Vice President, Drug Substance Development, Biohaven Yuhua Hu, Head of US/EU CMC Management, WuXi XDC	15:50-16:05 Roadshow
			16:05-16:20 Roadshow

2025BPD@Singapore Agenda

AM September 26	PM September 26
Session1-BPD Forum	Session1-BPD Forum
Regulatory and CMC Challenges in Cell Therapy	Advanced Technologies for Antibody Drugs
09:00-09:20 Keynote Speech: Cell Therapy Regulatory Landscape in China Speaker: Xiaoping Cao, CEO, IntelliScope PharmaSolutions 09:20-09:40 Keynote Speech: Key Inspection Points for CGT Products in China Speaker: Tu Bing, Bioproduct Inspection Group, Team Leader, Zhejiang Provincial Drug Inspection Center, China 09:40-10:00 Keynote Speech: Next-Generation CAR-T Development and Production Speaker: Guang Hu, VP of R&D, IASO 10:00-10:20 Keynote Speech: CMC and Process Development for TCR-T Speaker: SCG 10:20-10:40 Keynote Speech: Process Development for manufacturing of allogeneic NK and T cells Speaker: Andy Tan, Principal Scientist and Group Leader, Bioprocessing Technology Institute (BTI) 10:40-11:00 Keynote Speech: GMP Certification Process 11:00-11:20 Networking	13:00-13:20 Keynote Speech: Data Integrity Management in Biopharmaceutical Manufacturing Facilities Under the Global Regulatory Speaker: Dinesh Khokal, Global GxP Surveillance & Quality External Affairs, Global Technical Operations-Quality Excellence, BeiGene Singapore 13:20-13:40 Keynote Speech: Development and Optimization of High-Expression Cell Lines Speaker: Yang Yuansheng, Senior Principal Scientist II, Bioprocessing Technology Institute (BTI) 13:40-14:00 Keynote Speech: Down Stream Process Development of Bispecific Antibody Product Speaker: Zhang Wei, Principal Scientist & Group Leader, Downstream Processing, Bioprocessing Technology Institute (BTI) 14:00-14:20 Keynote Speech: Multilevel—Intact, Subunits, and Peptides—Characterization of Antibody-Based Therapeutics by a Single-Column LC—MS Setup Speaker: Bi Xuezhi, Associate Professor, Senior Principal Scientist I, Group Leader, Analytical Science & Technologies (Protein Analytics), Bioprocessing Technology Institute (BTI) 14:20-14:40 Keynote Speech: Considerations of Process Risks in the Technology Transfer of Drug Substance Production 14:40-15:00 Keynote Speech: Future Factories: Full Lifecycle Management of Biopharmaceutical Manufacturing Facilities
Bispecific Antibody Drugs Innovation	Advanced Technologies for Gene Therapy/mRNA/Nucleic Acid Drugs
11:20-11:40 Keynote Speech: Process Development of Bispecific TCE Products 11:40-12:00 Keynote Speech: CMC Strategy of Bispecific Antibodies at the IND Stage 12:00-12:20 Keynote Speech: Development of High-Concentration Antibody Drug Formulations	15:00-15:20 Keynote Speech: Gene Therapy Process Development and CMC Management 15:20-15:40 Keynote Speech: Chemical Modification and Delivery of Nucleic Acid Drugs 15:40-16:00 Keynote Speech: The Process Development and Production of mRNA Drugs
Session2- BPD Brainstorming	Session2- BPD Brainstorming
Antibody Drugs Case Study & Panel Discussion	Panel Discussion
09:00-09:20 Keynote Speech 09:20-09:40 Keynote Speech 09:40-10:00 Keynote Speech 10:00-11:00 Panel Discussion 11:00-11:20 Networking	13:00-14:00 Panel Discussion: CMC Considerations for Innovative Biologics Based on Global Development: Gene Therapy/mRNA/Nucleic Acid Drugs 14:00-15:00 Panel Discussion: Antibody Drugs Data Integrity and On-site Verification Panelist: Tu Bing, Bioproduct Inspection Group, Team Leader, Zhejiang Provincial Drug Inspection Center, China Dinesh Khokal, Global GxP Surveillance & Quality External Affairs, Global Technical Operations-Quality Excellence, BeiGene Singapore 15:00-16:00 Panel Discussion: Panel Discussion: Global Production Operations of Biologics: Efficiency and High Quality
Cell Therapy Case Study & Panel Discussion	
11:20-12:20 Panel Discussion: Cell Therapy CMC Challenges for Global Commercialization Panel Moderator: Xiaoping Cao, CEO, IntelliScope PharmaSolutions	

Biotech&Biopharma from Singapore and Southeast Asia

- VP/Director/Manager from Bioprocess Dept.
- VP/Director/Manager from Manufacture Dept.
- Director/Manager from Supply Chain Dept.
- Distributors and Agents from Singapore and Southeast Asia

Attendee

WuXi XDC global clients

- C-level/VP/Director from Pharma/Biopharma & Biotech in US/EU/APAC/CN

Biotech&Biopharma from China

- VP/Director from Bioprocess Dept.
- VP/Director from Manufacture Dept.
- C-level/BD of CDMO from China
- C-level/BD of Instruments, equipment, reagents, consumables, raw materials vendors from China



Enmore Bio, headquartered in Shanghai with branch offices in Jinan and Yantai, Shandong Province, has been at the forefront of fostering collaboration in the biotechnology and healthcare sectors since 2009. Through our innovative online portal and dynamic offline exhibitions, we seamlessly connect biotech, and pharmaceutical, service provider, capital partner, and healthcare institutions worldwide. Join us in creating a global biotech industry ecosystem, driving the conversion of cutting-edge biotechnologies into impactful clinical applications. We are proud to host BIOCHINA which is China's premier biotechnology industry convention.

